SAN DIEGO, July 8, 2020 /PRNewswire/ -- Affigen's Cancer Therapeutic Patent Portfolio addresses:
The Problem: The Signature Receptor is often unique from patient-to-patient necessitating a new drug for each patient within a clinically relevant time frame.
The Solution: The Signature Platform enables the production of patient-specific therapies against Signature Receptors with unprecedented speed and precision.
These therapies have the potential to bring a new class of safe and effective options to patients with Cancers, Autoimmune Diseases and Lymphoproliferative Disorders
About Heritage Global Inc. www.hginc.com
Heritage Global Inc. (OTCQB: HGBL, CSE: HGP) is a diversified financial services company providing acquisition, disposition, valuation and lending services for surplus and distressed assets.
About Heritage Global Patents & Trademarks
Heritage Global Patents & Trademarks is the Intellectual Property Division of Heritage Global Inc. and provides a patent monetization services via Patent Auctions and Patent Brokerage on its online monetization platform The Patent Exchange.
- Patents no longer part of strategic corporate objectives
- Patents which have never been commercialized nor developed and for which there are no plans to do so
- Unwanted patents representing ongoing renewal costs but whose market value declines with every year of non-use
- Orphan Patents acquired in mergers and acquisitions that are non-core and not needed
SOURCE Heritage Global Patents & Trademarks